Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05264506 · ClinicalTrials.gov registry record · Phase 3
Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive
A Phase 3 study, sponsored by Organon and.
- Terminated
- Registry status
- Phase 3
- Development phase
- 3,055
- Enrollment target
NCT05264506: Clinical Trial Phase 3 study, sponsored by Organon and.
NCT05264506 is a Phase 3 study that was terminated before completion, run by Organon and. The registered enrollment target is 3,055 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (296% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05264506, a Phase 3 study, was terminated before completion, sponsored by Organon and.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 3,055 participants
- Enrollment target
Study Summary
The purpose of this study is evaluating Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive in Premenopausal Females Aged 14 to 35 Years (Inclusive).
Primary Outcome
Raw count of the number of pregnancies that occurred while participants were taking study drug
Interventions
- DRUG NOMAC-E2 COC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,055 participants |
| Start Date | 2022-02-17 |
| Est. Completion | 2024-01-26 |
| Phase | Phase 3 |
Why NCT05264506 stopped before completion
NCT05264506 is an interventional study that assigns participants to a tested intervention. Its 3,055 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (296% higher).
The record links to 0 conditions, and to 1 intervention - of which NOMAC-E2 COC is the first listed.
NCT05264506 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05264506 about?
NCT05264506 is a clinical study titled "Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive". The purpose of this study is evaluating Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive in Premenopausal Females Aged 14 to 35 Years (Inclusive).
What is the current status of trial NCT05264506?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 3,055 participants. The study started on 2022-02-17. Estimated completion is 2024-01-26.
What interventions are being tested in trial NCT05264506?
The interventions under investigation include: NOMAC-E2 COC (DRUG).
Who is sponsoring clinical trial NCT05264506?
This trial is sponsored by Organon and, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05264506's enrollment target sits among peer trials
3,055 77th of 2000 higher than 1,924 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07116967 · 3,040 participants · Phase 3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
- NCT06667700 · 3,082 participants · Phase 3
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
- NCT05534243 · 3,090 participants · NA
The ED-AWARENESS-2 Trial
- NCT04722822 · 3,100 participants · NA
The HPV 9-10 Trial: Early Initiation of HPV Vaccination
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI